Germany · Delayed Price · Currency is EUR Scholar Rock Holding Company Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
Its transforming growth factor beta (TGFβ) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor.
The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.
Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2012 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 128 |
| CEO | David Hallal |
Contact Details
Address: 301 Binney Street Cambridge, Delaware 02142 United States | |
| Phone | 857 259 3860 |
| Website | scholarrock.com |
Stock Details
| Ticker Symbol | 2QK |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Hallal | Chief Executive Officer |
| Vikas Sinha | Chief Financial Officer |
| Robert Woods | Chief Operating Officer |
| Rushmie Nofsinger | Head of Investor Relations |